Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyOleandrin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Oleandrin
- Accession Number
- DB12843
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Description
Oleandrin has been used in trials studying the treatment of Lung Cancer and Chemotherapeutic Agent Toxicity.
- Structure
Structure for DB12843 (Oleandrin)
- Synonyms
- Anvirzel
- Oleandrina
- External IDs
- NSC-692219
- Categories
- UNII
- II95UDU7I4
- CAS number
- 465-16-7
- Weight
- Average: 576.727
Monoisotopic: 576.329833126 - Chemical Formula
- C32H48O9
- InChI Key
- JLPDBLFIVFSOCC-XYXFTTADSA-N
- InChI
- InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1
- IUPAC Name
- (1S,2S,5S,7R,10R,11S,13S,14R,15R)-11-hydroxy-5-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl acetate
- SMILES
- CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 10-hydroxycamptothecin Oleandrin may decrease the cardiotoxic activities of 10-hydroxycamptothecin. Investigational 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide Oleandrin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. Experimental 2-chloroethyl-3-sarcosinamide-1-nitrosourea Oleandrin may decrease the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea. Investigational 2-Methoxyestradiol Oleandrin may decrease the cardiotoxic activities of 2-Methoxyestradiol. Investigational 3-Methoxybenzamide Oleandrin may decrease the cardiotoxic activities of 3-Methoxybenzamide. Experimental 3,3'-diindolylmethane Oleandrin may decrease the cardiotoxic activities of 3,3'-diindolylmethane. Investigational 3,4-Dihydroxybenzoic Acid Oleandrin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid. Experimental 6-O-benzylguanine Oleandrin may decrease the cardiotoxic activities of 6-O-benzylguanine. Investigational 7-Hydroxystaurosporine Oleandrin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine. Experimental, Investigational 8-azaguanine Oleandrin may decrease the cardiotoxic activities of 8-azaguanine. Experimental 9-aminocamptothecin Oleandrin may decrease the cardiotoxic activities of 9-aminocamptothecin. Investigational Abiraterone Oleandrin may decrease the cardiotoxic activities of Abiraterone. Approved Acebutolol Acebutolol may increase the bradycardic activities of Oleandrin. Approved, Investigational Aclarubicin Oleandrin may decrease the cardiotoxic activities of Aclarubicin. Investigational Acridine Carboxamide Oleandrin may decrease the cardiotoxic activities of Acridine Carboxamide. Investigational Acteoside Oleandrin may decrease the cardiotoxic activities of Acteoside. Investigational Afatinib Oleandrin may decrease the cardiotoxic activities of Afatinib. Approved Afimoxifene Oleandrin may decrease the cardiotoxic activities of Afimoxifene. Investigational Aflibercept Oleandrin may decrease the cardiotoxic activities of Aflibercept. Approved Alanosine Oleandrin may decrease the cardiotoxic activities of Alanosine. Investigational Alatrofloxacin Oleandrin may decrease the cardiotoxic activities of Alatrofloxacin. Withdrawn Albendazole Oleandrin may decrease the cardiotoxic activities of Albendazole. Approved, Vet Approved Alcuronium Alcuronium may increase the arrhythmogenic activities of Oleandrin. Experimental Aldesleukin Oleandrin may decrease the cardiotoxic activities of Aldesleukin. Approved Alectinib Oleandrin may decrease the cardiotoxic activities of Alectinib. Approved, Investigational Alemtuzumab Oleandrin may decrease the cardiotoxic activities of Alemtuzumab. Approved, Investigational Alfacalcidol Alfacalcidol may increase the arrhythmogenic activities of Oleandrin. Approved, Nutraceutical Alitretinoin Oleandrin may decrease the cardiotoxic activities of Alitretinoin. Approved, Investigational Alprenolol Alprenolol may increase the bradycardic activities of Oleandrin. Approved, Withdrawn Altretamine Oleandrin may decrease the cardiotoxic activities of Altretamine. Approved Alvocidib Oleandrin may decrease the cardiotoxic activities of Alvocidib. Experimental, Investigational Amikacin The serum concentration of Oleandrin can be decreased when it is combined with Amikacin. Approved, Investigational, Vet Approved Amiloride The therapeutic efficacy of Oleandrin can be decreased when used in combination with Amiloride. Approved Aminoglutethimide Oleandrin may decrease the cardiotoxic activities of Aminoglutethimide. Approved, Investigational Aminolevulinic acid Oleandrin may decrease the cardiotoxic activities of Aminolevulinic acid. Approved Amiodarone The serum concentration of Oleandrin can be increased when it is combined with Amiodarone. Approved, Investigational Amodiaquine The serum concentration of Oleandrin can be increased when it is combined with Amodiaquine. Approved, Investigational Amonafide Oleandrin may decrease the cardiotoxic activities of Amonafide. Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Oleandrin. Approved, Investigational Amrubicin Oleandrin may decrease the cardiotoxic activities of Amrubicin. Approved, Investigational Amsacrine Oleandrin may decrease the cardiotoxic activities of Amsacrine. Approved, Investigational Anagrelide Oleandrin may decrease the cardiotoxic activities of Anagrelide. Approved Anastrozole Oleandrin may decrease the cardiotoxic activities of Anastrozole. Approved, Investigational Anecortave Oleandrin may decrease the cardiotoxic activities of Anecortave. Investigational Annamycin Oleandrin may decrease the cardiotoxic activities of Annamycin. Investigational AP 12009 Oleandrin may decrease the cardiotoxic activities of AP 12009. Investigational Apaziquone Oleandrin may decrease the cardiotoxic activities of Apaziquone. Investigational Apramycin The serum concentration of Oleandrin can be decreased when it is combined with Apramycin. Experimental, Vet Approved Arbekacin The serum concentration of Oleandrin can be decreased when it is combined with Arbekacin. Approved, Investigational Arotinoid acid Oleandrin may decrease the cardiotoxic activities of Arotinoid acid. Experimental Arotinolol Arotinolol may increase the bradycardic activities of Oleandrin. Investigational Arsanilic acid Oleandrin may decrease the cardiotoxic activities of Arsanilic acid. Experimental, Vet Approved Arsenic trioxide Oleandrin may decrease the cardiotoxic activities of Arsenic trioxide. Approved, Investigational Asenapine Asenapine may increase the bradycardic activities of Oleandrin. Approved Asparaginase Erwinia chrysanthemi Oleandrin may decrease the cardiotoxic activities of Asparaginase Erwinia chrysanthemi. Approved, Investigational Asparaginase Escherichia coli Oleandrin may decrease the cardiotoxic activities of Asparaginase Escherichia coli. Approved, Investigational Atenolol Atenolol may increase the bradycardic activities of Oleandrin. Approved Atezolizumab Oleandrin may decrease the cardiotoxic activities of Atezolizumab. Approved, Investigational Atracurium Atracurium may increase the arrhythmogenic activities of Oleandrin. Approved, Experimental, Investigational Atracurium besylate Atracurium besylate may increase the arrhythmogenic activities of Oleandrin. Approved Avelumab Oleandrin may decrease the cardiotoxic activities of Avelumab. Approved, Investigational Axitinib Oleandrin may decrease the cardiotoxic activities of Axitinib. Approved, Investigational Azacitidine Oleandrin may decrease the cardiotoxic activities of Azacitidine. Approved, Investigational Azathioprine Oleandrin may decrease the cardiotoxic activities of Azathioprine. Approved Azelaic Acid Oleandrin may decrease the cardiotoxic activities of Azelaic Acid. Approved Azithromycin The serum concentration of Oleandrin can be increased when it is combined with Azithromycin. Approved Azosemide The risk or severity of adverse effects can be increased when Azosemide is combined with Oleandrin. Investigational Balsalazide The serum concentration of Oleandrin can be decreased when it is combined with Balsalazide. Approved, Investigational Batimastat Oleandrin may decrease the cardiotoxic activities of Batimastat. Experimental Befunolol Befunolol may increase the bradycardic activities of Oleandrin. Experimental Bekanamycin The serum concentration of Oleandrin can be decreased when it is combined with Bekanamycin. Experimental Belinostat Oleandrin may decrease the cardiotoxic activities of Belinostat. Approved, Investigational Belotecan Oleandrin may decrease the cardiotoxic activities of Belotecan. Investigational Bendamustine Oleandrin may decrease the cardiotoxic activities of Bendamustine. Approved, Investigational Bendroflumethiazide The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Oleandrin. Approved Benzthiazide The risk or severity of adverse effects can be increased when Benzthiazide is combined with Oleandrin. Approved Besifloxacin Oleandrin may decrease the cardiotoxic activities of Besifloxacin. Approved Betaxolol Betaxolol may increase the bradycardic activities of Oleandrin. Approved, Investigational Bevacizumab Oleandrin may decrease the cardiotoxic activities of Bevacizumab. Approved, Investigational Bevantolol Bevantolol may increase the bradycardic activities of Oleandrin. Approved Bexarotene Oleandrin may decrease the cardiotoxic activities of Bexarotene. Approved, Investigational Bicalutamide Oleandrin may decrease the cardiotoxic activities of Bicalutamide. Approved Binetrakin Oleandrin may decrease the cardiotoxic activities of Binetrakin. Investigational Bisoprolol Bisoprolol may increase the bradycardic activities of Oleandrin. Approved Bizelesin Oleandrin may decrease the cardiotoxic activities of Bizelesin. Investigational Bleomycin Oleandrin may decrease the cardiotoxic activities of Bleomycin. Approved, Investigational Blinatumomab Oleandrin may decrease the cardiotoxic activities of Blinatumomab. Approved, Investigational Bopindolol Bopindolol may increase the bradycardic activities of Oleandrin. Approved Bortezomib Oleandrin may decrease the cardiotoxic activities of Bortezomib. Approved, Investigational Bosutinib Oleandrin may decrease the cardiotoxic activities of Bosutinib. Approved Brentuximab vedotin Oleandrin may decrease the cardiotoxic activities of Brentuximab vedotin. Approved, Investigational Broxuridine Oleandrin may decrease the cardiotoxic activities of Broxuridine. Investigational Bryostatin 1 Oleandrin may decrease the cardiotoxic activities of Bryostatin 1. Investigational Bucindolol Bucindolol may increase the bradycardic activities of Oleandrin. Investigational Bufuralol Bufuralol may increase the bradycardic activities of Oleandrin. Experimental, Investigational Bumetanide The risk or severity of adverse effects can be increased when Bumetanide is combined with Oleandrin. Approved Bupranolol Bupranolol may increase the bradycardic activities of Oleandrin. Approved Buserelin Oleandrin may decrease the cardiotoxic activities of Buserelin. Approved, Investigational Busulfan Oleandrin may decrease the cardiotoxic activities of Busulfan. Approved, Investigational Buthionine Sulfoximine Oleandrin may decrease the cardiotoxic activities of Buthionine Sulfoximine. Investigational Cabazitaxel Oleandrin may decrease the cardiotoxic activities of Cabazitaxel. Approved Cabergoline Oleandrin may decrease the cardiotoxic activities of Cabergoline. Approved Cabozantinib Oleandrin may decrease the cardiotoxic activities of Cabozantinib. Approved, Investigational Calcidiol Calcidiol may increase the arrhythmogenic activities of Oleandrin. Approved, Nutraceutical Calcipotriol Oleandrin may decrease the cardiotoxic activities of Calcipotriol. Approved Calcitriol Calcitriol may increase the arrhythmogenic activities of Oleandrin. Approved, Nutraceutical Calcium Acetate Calcium Acetate may increase the arrhythmogenic activities of Oleandrin. Approved, Investigational Calcium Carbonate Calcium Carbonate may increase the arrhythmogenic activities of Oleandrin. Approved, Investigational Calcium Chloride Calcium Chloride may increase the arrhythmogenic activities of Oleandrin. Approved Calcium Citrate Calcium Citrate may increase the arrhythmogenic activities of Oleandrin. Approved Calcium glubionate Calcium glubionate may increase the arrhythmogenic activities of Oleandrin. Approved Calcium Gluceptate Calcium Gluceptate may increase the arrhythmogenic activities of Oleandrin. Approved Calcium gluconate Calcium gluconate may increase the arrhythmogenic activities of Oleandrin. Approved, Vet Approved Calcium lactate Calcium lactate may increase the arrhythmogenic activities of Oleandrin. Approved, Investigational, Vet Approved Calcium lactate gluconate Calcium lactate gluconate may increase the arrhythmogenic activities of Oleandrin. Experimental Calcium levulinate Calcium levulinate may increase the arrhythmogenic activities of Oleandrin. Approved, Experimental Calcium pangamate Calcium pangamate may increase the arrhythmogenic activities of Oleandrin. Experimental Calcium Phosphate Calcium Phosphate may increase the arrhythmogenic activities of Oleandrin. Approved Camptothecin Oleandrin may decrease the cardiotoxic activities of Camptothecin. Experimental Canertinib Oleandrin may decrease the cardiotoxic activities of Canertinib. Investigational Capecitabine Oleandrin may decrease the cardiotoxic activities of Capecitabine. Approved, Investigational Carbimazole The serum concentration of Oleandrin can be increased when it is combined with Carbimazole. Approved, Investigational Carbomycin The serum concentration of Oleandrin can be increased when it is combined with Carbomycin. Vet Approved Carboplatin Oleandrin may decrease the cardiotoxic activities of Carboplatin. Approved Carboquone Oleandrin may decrease the cardiotoxic activities of Carboquone. Experimental Carboxyamidotriazole Oleandrin may decrease the cardiotoxic activities of Carboxyamidotriazole. Investigational Carfilzomib Oleandrin may decrease the cardiotoxic activities of Carfilzomib. Approved, Investigational Carmofur Oleandrin may decrease the cardiotoxic activities of Carmofur. Withdrawn Carmustine Oleandrin may decrease the cardiotoxic activities of Carmustine. Approved, Investigational Carteolol Carteolol may increase the bradycardic activities of Oleandrin. Approved Carvedilol Carvedilol may increase the bradycardic activities of Oleandrin. Approved, Investigational Casein Casein may increase the arrhythmogenic activities of Oleandrin. Approved Catumaxomab Oleandrin may decrease the cardiotoxic activities of Catumaxomab. Approved, Investigational, Withdrawn Cediranib Oleandrin may decrease the cardiotoxic activities of Cediranib. Investigational Celecoxib Oleandrin may decrease the cardiotoxic activities of Celecoxib. Approved, Investigational Celiprolol Celiprolol may increase the bradycardic activities of Oleandrin. Approved, Investigational Ceritinib Oleandrin may decrease the cardiotoxic activities of Ceritinib. Approved Cetuximab Oleandrin may decrease the cardiotoxic activities of Cetuximab. Approved Chlorambucil Oleandrin may decrease the cardiotoxic activities of Chlorambucil. Approved Chloroquine The serum concentration of Oleandrin can be increased when it is combined with Chloroquine. Approved, Investigational, Vet Approved Chlorothiazide The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Oleandrin. Approved, Vet Approved Chlorotrianisene Oleandrin may decrease the cardiotoxic activities of Chlorotrianisene. Investigational, Withdrawn Chlorthalidone The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Oleandrin. Approved Cholecalciferol Cholecalciferol may increase the arrhythmogenic activities of Oleandrin. Approved, Nutraceutical Cholestyramine Cholestyramine can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Cinoxacin Oleandrin may decrease the cardiotoxic activities of Cinoxacin. Approved, Investigational, Withdrawn Ciprofloxacin Oleandrin may decrease the cardiotoxic activities of Ciprofloxacin. Approved, Investigational Cisatracurium Cisatracurium may increase the arrhythmogenic activities of Oleandrin. Approved Cisplatin Oleandrin may decrease the cardiotoxic activities of Cisplatin. Approved Cladribine Oleandrin may decrease the cardiotoxic activities of Cladribine. Approved, Investigational Clarithromycin The serum concentration of Oleandrin can be increased when it is combined with Clarithromycin. Approved Clinafloxacin Oleandrin may decrease the cardiotoxic activities of Clinafloxacin. Investigational Clofarabine Oleandrin may decrease the cardiotoxic activities of Clofarabine. Approved, Investigational Clonidine Clonidine may increase the atrioventricular blocking (AV block) activities of Oleandrin. Approved Cloranolol Cloranolol may increase the bradycardic activities of Oleandrin. Experimental Cobimetinib Oleandrin may decrease the cardiotoxic activities of Cobimetinib. Approved, Investigational Colchicine Oleandrin may decrease the cardiotoxic activities of Colchicine. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Combretastatin Oleandrin may decrease the cardiotoxic activities of Combretastatin. Investigational Cordycepin Oleandrin may decrease the cardiotoxic activities of Cordycepin. Investigational Coumermycin A1 Oleandrin may decrease the cardiotoxic activities of Coumermycin A1. Experimental Crenolanib Oleandrin may decrease the cardiotoxic activities of Crenolanib. Investigational Crizotinib Oleandrin may decrease the cardiotoxic activities of Crizotinib. Approved Curcumin Oleandrin may decrease the cardiotoxic activities of Curcumin. Approved, Investigational Cyclopenthiazide The risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Oleandrin. Experimental Cyclophosphamide Oleandrin may decrease the cardiotoxic activities of Cyclophosphamide. Approved, Investigational Cyproterone acetate Oleandrin may decrease the cardiotoxic activities of Cyproterone acetate. Approved, Investigational Cytarabine Oleandrin may decrease the cardiotoxic activities of Cytarabine. Approved, Investigational Dabrafenib Oleandrin may decrease the cardiotoxic activities of Dabrafenib. Approved, Investigational Dacarbazine Oleandrin may decrease the cardiotoxic activities of Dacarbazine. Approved, Investigational Dactinomycin Oleandrin may decrease the cardiotoxic activities of Dactinomycin. Approved, Investigational Daidzein Oleandrin may decrease the cardiotoxic activities of Daidzein. Experimental Daratumumab Oleandrin may decrease the cardiotoxic activities of Daratumumab. Approved Dasatinib Oleandrin may decrease the cardiotoxic activities of Dasatinib. Approved, Investigational Daunorubicin Oleandrin may decrease the cardiotoxic activities of Daunorubicin. Approved Decamethonium Decamethonium may increase the arrhythmogenic activities of Oleandrin. Approved Decitabine Oleandrin may decrease the cardiotoxic activities of Decitabine. Approved, Investigational Degarelix Oleandrin may decrease the cardiotoxic activities of Degarelix. Approved Demecolcine Oleandrin may decrease the cardiotoxic activities of Demecolcine. Experimental Denileukin diftitox Oleandrin may decrease the cardiotoxic activities of Denileukin diftitox. Approved, Investigational Deoxyspergualin Oleandrin may decrease the cardiotoxic activities of Deoxyspergualin. Investigational Desipramine Desipramine may increase the bradycardic activities of Oleandrin. Approved, Investigational Dexamethasone Oleandrin may decrease the cardiotoxic activities of Dexamethasone. Approved, Investigational, Vet Approved Dexrazoxane Oleandrin may decrease the cardiotoxic activities of Dexrazoxane. Approved, Withdrawn Dianhydrogalactitol Oleandrin may decrease the cardiotoxic activities of Dianhydrogalactitol. Investigational Dibekacin The serum concentration of Oleandrin can be decreased when it is combined with Dibekacin. Experimental Didox Oleandrin may decrease the cardiotoxic activities of Didox. Investigational Dienogest Oleandrin may decrease the cardiotoxic activities of Dienogest. Approved Diethylnorspermine Oleandrin may decrease the cardiotoxic activities of Diethylnorspermine. Investigational Diethylstilbestrol Oleandrin may decrease the cardiotoxic activities of Diethylstilbestrol. Approved, Investigational Dihydrostreptomycin The serum concentration of Oleandrin can be decreased when it is combined with Dihydrostreptomycin. Investigational, Vet Approved Dihydrotachysterol Dihydrotachysterol may increase the arrhythmogenic activities of Oleandrin. Approved Diltiazem Diltiazem may increase the atrioventricular blocking (AV block) activities of Oleandrin. Approved, Investigational Dinutuximab Oleandrin may decrease the cardiotoxic activities of Dinutuximab. Approved, Investigational Docetaxel Oleandrin may decrease the cardiotoxic activities of Docetaxel. Approved, Investigational Dolastatin 10 Oleandrin may decrease the cardiotoxic activities of Dolastatin 10. Investigational Domoic Acid Domoic Acid may increase the arrhythmogenic activities of Oleandrin. Experimental Doxacurium Doxacurium chloride may increase the arrhythmogenic activities of Oleandrin. Approved Doxercalciferol Doxercalciferol may increase the arrhythmogenic activities of Oleandrin. Approved Doxifluridine Oleandrin may decrease the cardiotoxic activities of Doxifluridine. Investigational Doxorubicin Oleandrin may decrease the cardiotoxic activities of Doxorubicin. Approved, Investigational Duligotuzumab Oleandrin may decrease the cardiotoxic activities of Duligotuzumab. Investigational Durvalumab Oleandrin may decrease the cardiotoxic activities of Durvalumab. Approved, Investigational Ecabet Oleandrin may decrease the cardiotoxic activities of Ecabet. Approved, Investigational Edrecolomab Oleandrin may decrease the cardiotoxic activities of Edrecolomab. Experimental, Investigational Edrophonium Edrophonium may increase the atrioventricular blocking (AV block) activities of Oleandrin. Approved Efaproxiral Oleandrin may decrease the cardiotoxic activities of Efaproxiral. Investigational Efatutazone Oleandrin may decrease the cardiotoxic activities of Efatutazone. Investigational Eflornithine Oleandrin may decrease the cardiotoxic activities of Eflornithine. Approved, Withdrawn EG009 Oleandrin may decrease the cardiotoxic activities of EG009. Investigational Elotuzumab Oleandrin may decrease the cardiotoxic activities of Elotuzumab. Approved Elsamitrucin Oleandrin may decrease the cardiotoxic activities of Elsamitrucin. Investigational Endostatin Oleandrin may decrease the cardiotoxic activities of Endostatin. Investigational Enoxacin Oleandrin may decrease the cardiotoxic activities of Enoxacin. Approved, Investigational Enrofloxacin Oleandrin may decrease the cardiotoxic activities of Enrofloxacin. Vet Approved Entinostat Oleandrin may decrease the cardiotoxic activities of Entinostat. Investigational Enzalutamide Oleandrin may decrease the cardiotoxic activities of Enzalutamide. Approved Epanolol Epanolol may increase the bradycardic activities of Oleandrin. Experimental Epigallocatechin Gallate Oleandrin may decrease the cardiotoxic activities of Epigallocatechin Gallate. Investigational Epirubicin Oleandrin may decrease the cardiotoxic activities of Epirubicin. Approved Epitizide The risk or severity of adverse effects can be increased when Epitizide is combined with Oleandrin. Experimental Eplerenone The therapeutic efficacy of Oleandrin can be decreased when used in combination with Eplerenone. Approved Epofolate Oleandrin may decrease the cardiotoxic activities of Epofolate. Investigational Ergocalciferol Ergocalciferol may increase the arrhythmogenic activities of Oleandrin. Approved, Nutraceutical Eribulin Oleandrin may decrease the cardiotoxic activities of Eribulin. Approved, Investigational Erlotinib Oleandrin may decrease the cardiotoxic activities of Erlotinib. Approved, Investigational Erythromycin The serum concentration of Oleandrin can be increased when it is combined with Erythromycin. Approved, Investigational, Vet Approved Esatenolol Esatenolol may increase the bradycardic activities of Oleandrin. Experimental Esmolol Esmolol may increase the bradycardic activities of Oleandrin. Approved Estramustine Oleandrin may decrease the cardiotoxic activities of Estramustine. Approved, Investigational Etacrynic acid The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oleandrin. Approved, Investigational Etanidazole Oleandrin may decrease the cardiotoxic activities of Etanidazole. Investigational Ethiodized oil Oleandrin may decrease the cardiotoxic activities of Ethiodized oil. Approved, Investigational Ethyl carbamate Oleandrin may decrease the cardiotoxic activities of Ethyl carbamate. Withdrawn Etoglucid Oleandrin may decrease the cardiotoxic activities of Etoglucid. Experimental Etoposide Oleandrin may decrease the cardiotoxic activities of Etoposide. Approved Everolimus Oleandrin may decrease the cardiotoxic activities of Everolimus. Approved Exatecan Oleandrin may decrease the cardiotoxic activities of Exatecan. Investigational Exemestane Oleandrin may decrease the cardiotoxic activities of Exemestane. Approved, Investigational Exisulind Oleandrin may decrease the cardiotoxic activities of Exisulind. Investigational Fenretinide Oleandrin may decrease the cardiotoxic activities of Fenretinide. Investigational Fiacitabine Oleandrin may decrease the cardiotoxic activities of Fiacitabine. Investigational Fleroxacin Oleandrin may decrease the cardiotoxic activities of Fleroxacin. Approved Floxuridine Oleandrin may decrease the cardiotoxic activities of Floxuridine. Approved Fludarabine Oleandrin may decrease the cardiotoxic activities of Fludarabine. Approved Flumequine Oleandrin may decrease the cardiotoxic activities of Flumequine. Withdrawn Fluorouracil Oleandrin may decrease the cardiotoxic activities of Fluorouracil. Approved Flutamide Oleandrin may decrease the cardiotoxic activities of Flutamide. Approved, Investigational Formestane Oleandrin may decrease the cardiotoxic activities of Formestane. Approved, Investigational, Withdrawn Formycin Oleandrin may decrease the cardiotoxic activities of Formycin. Experimental Fosbretabulin Oleandrin may decrease the cardiotoxic activities of Fosbretabulin. Investigational Fotemustine Oleandrin may decrease the cardiotoxic activities of Fotemustine. Experimental, Investigational Framycetin The serum concentration of Oleandrin can be decreased when it is combined with Framycetin. Approved Fulvestrant Oleandrin may decrease the cardiotoxic activities of Fulvestrant. Approved, Investigational Fumagillin Oleandrin may decrease the cardiotoxic activities of Fumagillin. Experimental Furosemide The risk or severity of adverse effects can be increased when Furosemide is combined with Oleandrin. Approved, Vet Approved Gallamine Gallamine may increase the arrhythmogenic activities of Oleandrin. Experimental Gallamine Triethiodide Gallamine Triethiodide may increase the arrhythmogenic activities of Oleandrin. Approved Gallium nitrate Oleandrin may decrease the cardiotoxic activities of Gallium nitrate. Approved, Investigational Garenoxacin Oleandrin may decrease the cardiotoxic activities of Garenoxacin. Investigational Gatifloxacin Oleandrin may decrease the cardiotoxic activities of Gatifloxacin. Approved, Investigational Gefitinib Oleandrin may decrease the cardiotoxic activities of Gefitinib. Approved, Investigational Geldanamycin Oleandrin may decrease the cardiotoxic activities of Geldanamycin. Experimental, Investigational Gemcitabine Oleandrin may decrease the cardiotoxic activities of Gemcitabine. Approved Gemifloxacin Oleandrin may decrease the cardiotoxic activities of Gemifloxacin. Approved, Investigational Gemtuzumab ozogamicin Oleandrin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin. Approved, Investigational Geneticin The serum concentration of Oleandrin can be decreased when it is combined with Geneticin. Experimental Genistein Oleandrin may decrease the cardiotoxic activities of Genistein. Investigational Gentamicin The serum concentration of Oleandrin can be decreased when it is combined with Gentamicin. Approved, Vet Approved GENTAMICIN C1A The serum concentration of Oleandrin can be decreased when it is combined with GENTAMICIN C1A. Experimental Ginsenoside C Oleandrin may decrease the cardiotoxic activities of Ginsenoside C. Nutraceutical Goserelin Oleandrin may decrease the cardiotoxic activities of Goserelin. Approved Grepafloxacin Oleandrin may decrease the cardiotoxic activities of Grepafloxacin. Approved, Investigational, Withdrawn GS 0573 Oleandrin may decrease the cardiotoxic activities of GS 0573. Investigational Gusperimus Oleandrin may decrease the cardiotoxic activities of Gusperimus. Investigational Hadacidin Oleandrin may decrease the cardiotoxic activities of Hadacidin. Experimental Halofuginone Oleandrin may decrease the cardiotoxic activities of Halofuginone. Investigational, Vet Approved Hexestrol Oleandrin may decrease the cardiotoxic activities of Hexestrol. Withdrawn Hydrochlorothiazide The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Oleandrin. Approved, Vet Approved Hydroflumethiazide The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Oleandrin. Approved, Investigational Hydroxychloroquine The serum concentration of Oleandrin can be increased when it is combined with Hydroxychloroquine. Approved Hydroxyprogesterone caproate Oleandrin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate. Approved, Investigational Hydroxyurea Oleandrin may decrease the cardiotoxic activities of Hydroxyurea. Approved Hygromycin B The serum concentration of Oleandrin can be decreased when it is combined with Hygromycin B. Vet Approved Hypericin Oleandrin may decrease the cardiotoxic activities of Hypericin. Investigational Ibrutinib Oleandrin may decrease the cardiotoxic activities of Ibrutinib. Approved Idarubicin Oleandrin may decrease the cardiotoxic activities of Idarubicin. Approved Idelalisib Oleandrin may decrease the cardiotoxic activities of Idelalisib. Approved Ifosfamide Oleandrin may decrease the cardiotoxic activities of Ifosfamide. Approved Imatinib Oleandrin may decrease the cardiotoxic activities of Imatinib. Approved Imiquimod Oleandrin may decrease the cardiotoxic activities of Imiquimod. Approved, Investigational Indapamide The risk or severity of adverse effects can be increased when Indapamide is combined with Oleandrin. Approved Indenolol Indenolol may increase the bradycardic activities of Oleandrin. Withdrawn Indirubin Oleandrin may decrease the cardiotoxic activities of Indirubin. Investigational Indole-3-carbinol Oleandrin may decrease the cardiotoxic activities of Indole-3-carbinol. Investigational Infigratinib Oleandrin may decrease the cardiotoxic activities of Infigratinib. Investigational Iniparib Oleandrin may decrease the cardiotoxic activities of Iniparib. Investigational Inotuzumab ozogamicin Oleandrin may decrease the cardiotoxic activities of Inotuzumab ozogamicin. Approved, Investigational Interferon Alfa-2b, Recombinant Oleandrin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant. Approved Interferon beta-1a Oleandrin may decrease the cardiotoxic activities of Interferon beta-1a. Approved, Investigational Iobenguane Oleandrin may decrease the cardiotoxic activities of Iobenguane. Approved, Investigational Ipilimumab Oleandrin may decrease the cardiotoxic activities of Ipilimumab. Approved Irinotecan Oleandrin may decrease the cardiotoxic activities of Irinotecan. Approved, Investigational Irofulven Oleandrin may decrease the cardiotoxic activities of Irofulven. Investigational Irsogladine Oleandrin may decrease the cardiotoxic activities of Irsogladine. Investigational Isepamicin The serum concentration of Oleandrin can be decreased when it is combined with Isepamicin. Experimental Isosorbide Oleandrin may decrease the cardiotoxic activities of Isosorbide. Approved, Investigational Itraconazole The serum concentration of Oleandrin can be increased when it is combined with Itraconazole. Approved, Investigational Ixabepilone Oleandrin may decrease the cardiotoxic activities of Ixabepilone. Approved, Investigational Ixazomib Oleandrin may decrease the cardiotoxic activities of Ixazomib. Approved, Investigational Josamycin The serum concentration of Oleandrin can be increased when it is combined with Josamycin. Approved, Investigational Kanamycin The serum concentration of Oleandrin can be decreased when it is combined with Kanamycin. Approved, Investigational, Vet Approved Kaolin The serum concentration of Oleandrin can be decreased when it is combined with Kaolin. Approved Kitasamycin The serum concentration of Oleandrin can be increased when it is combined with Kitasamycin. Experimental KOS-1584 Oleandrin may decrease the cardiotoxic activities of KOS-1584. Investigational KRN-7000 Oleandrin may decrease the cardiotoxic activities of KRN-7000. Investigational Labetalol Labetalol may increase the bradycardic activities of Oleandrin. Approved Landiolol Landiolol may increase the bradycardic activities of Oleandrin. Investigational Lanreotide Oleandrin may decrease the cardiotoxic activities of Lanreotide. Approved Lapatinib Oleandrin may decrease the cardiotoxic activities of Lapatinib. Approved, Investigational LCL-161 Oleandrin may decrease the cardiotoxic activities of LCL-161. Investigational Leflunomide Oleandrin may decrease the cardiotoxic activities of Leflunomide. Approved, Investigational Lenalidomide Oleandrin may decrease the cardiotoxic activities of Lenalidomide. Approved Lentinan Oleandrin may decrease the cardiotoxic activities of Lentinan. Experimental, Investigational Lenvatinib Oleandrin may decrease the cardiotoxic activities of Lenvatinib. Approved, Investigational Letrozole Oleandrin may decrease the cardiotoxic activities of Letrozole. Approved, Investigational Leuprolide Oleandrin may decrease the cardiotoxic activities of Leuprolide. Approved, Investigational Levobetaxolol Levobetaxolol may increase the bradycardic activities of Oleandrin. Approved, Investigational Levobunolol Levobunolol may increase the bradycardic activities of Oleandrin. Approved Levofloxacin Oleandrin may decrease the cardiotoxic activities of Levofloxacin. Approved, Investigational Liarozole Oleandrin may decrease the cardiotoxic activities of Liarozole. Investigational Licorice The risk or severity of adverse effects can be increased when Licorice is combined with Oleandrin. Approved Lomefloxacin Oleandrin may decrease the cardiotoxic activities of Lomefloxacin. Approved, Investigational Lometrexol Oleandrin may decrease the cardiotoxic activities of Lometrexol. Investigational Lomustine Oleandrin may decrease the cardiotoxic activities of Lomustine. Approved, Investigational Lonidamine Oleandrin may decrease the cardiotoxic activities of Lonidamine. Investigational Lurtotecan Oleandrin may decrease the cardiotoxic activities of Lurtotecan. Investigational Lycopene Oleandrin may decrease the cardiotoxic activities of Lycopene. Approved, Investigational Mafosfamide Oleandrin may decrease the cardiotoxic activities of Mafosfamide. Investigational Mannosulfan Oleandrin may decrease the cardiotoxic activities of Mannosulfan. Experimental Masitinib Oleandrin may decrease the cardiotoxic activities of Masitinib. Investigational, Vet Approved Masoprocol Oleandrin may decrease the cardiotoxic activities of Masoprocol. Approved, Investigational Maxacalcitol Oleandrin may decrease the cardiotoxic activities of Maxacalcitol. Approved, Investigational Mebendazole Oleandrin may decrease the cardiotoxic activities of Mebendazole. Approved, Vet Approved Mechlorethamine Oleandrin may decrease the cardiotoxic activities of Mechlorethamine. Approved, Investigational Medrogestone Oleandrin may decrease the cardiotoxic activities of Medrogestone. Approved Medroxyprogesterone acetate Oleandrin may decrease the cardiotoxic activities of Medroxyprogesterone acetate. Approved, Investigational Megestrol acetate Oleandrin may decrease the cardiotoxic activities of Megestrol acetate. Approved, Investigational, Vet Approved Melphalan Oleandrin may decrease the cardiotoxic activities of Melphalan. Approved Mepindolol Mepindolol may increase the bradycardic activities of Oleandrin. Experimental Mequinol Oleandrin may decrease the cardiotoxic activities of Mequinol. Approved Mercaptopurine Oleandrin may decrease the cardiotoxic activities of Mercaptopurine. Approved Merestinib Oleandrin may decrease the cardiotoxic activities of Merestinib. Investigational Mesalazine The serum concentration of Oleandrin can be decreased when it is combined with Mesalazine. Approved Methimazole The serum concentration of Oleandrin can be increased when it is combined with Methimazole. Approved Methotrexate Oleandrin may decrease the cardiotoxic activities of Methotrexate. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Oleandrin. Approved Methyl aminolevulinate Oleandrin may decrease the cardiotoxic activities of Methyl aminolevulinate. Approved, Investigational Methylprednisolone Oleandrin may decrease the cardiotoxic activities of Methylprednisolone. Approved, Vet Approved Methylselenocysteine Oleandrin may decrease the cardiotoxic activities of Methylselenocysteine. Investigational Methyltestosterone Oleandrin may decrease the cardiotoxic activities of Methyltestosterone. Approved Methylthiouracil The serum concentration of Oleandrin can be increased when it is combined with Methylthiouracil. Experimental Metipranolol Metipranolol may increase the bradycardic activities of Oleandrin. Approved Metocurine Metocurine may increase the arrhythmogenic activities of Oleandrin. Approved Metocurine Iodide Metocurine Iodide may increase the arrhythmogenic activities of Oleandrin. Approved, Withdrawn Metolazone The risk or severity of adverse effects can be increased when Metolazone is combined with Oleandrin. Approved Metoprine Oleandrin may decrease the cardiotoxic activities of Metoprine. Experimental Metoprolol Metoprolol may increase the bradycardic activities of Oleandrin. Approved, Investigational Micronomicin The serum concentration of Oleandrin can be decreased when it is combined with Micronomicin. Experimental Midodrine Oleandrin may increase the bradycardic activities of Midodrine. Approved Midostaurin Oleandrin may decrease the cardiotoxic activities of Midostaurin. Approved, Investigational Miltefosine Oleandrin may decrease the cardiotoxic activities of Miltefosine. Approved, Investigational Misonidazole Oleandrin may decrease the cardiotoxic activities of Misonidazole. Investigational Mitobronitol Oleandrin may decrease the cardiotoxic activities of Mitobronitol. Experimental Mitoguazone Oleandrin may decrease the cardiotoxic activities of Mitoguazone. Investigational Mitolactol Oleandrin may decrease the cardiotoxic activities of Mitolactol. Investigational Mitomycin Oleandrin may decrease the cardiotoxic activities of Mitomycin. Approved Mitotane Oleandrin may decrease the cardiotoxic activities of Mitotane. Approved Mitoxantrone Oleandrin may decrease the cardiotoxic activities of Mitoxantrone. Approved, Investigational Mivacurium Mivacurium may increase the arrhythmogenic activities of Oleandrin. Approved Mizoribine Oleandrin may decrease the cardiotoxic activities of Mizoribine. Investigational MLN576 Oleandrin may decrease the cardiotoxic activities of MLN576. Investigational Molgramostim Oleandrin may decrease the cardiotoxic activities of Molgramostim. Investigational motexafin gadolinium Oleandrin may decrease the cardiotoxic activities of motexafin gadolinium. Investigational Moxifloxacin Oleandrin may decrease the cardiotoxic activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil Oleandrin may decrease the cardiotoxic activities of Mycophenolate mofetil. Approved, Investigational Mycophenolic acid Oleandrin may decrease the cardiotoxic activities of Mycophenolic acid. Approved Nadifloxacin Oleandrin may decrease the cardiotoxic activities of Nadifloxacin. Investigational Nadolol Nadolol may increase the bradycardic activities of Oleandrin. Approved Nalidixic Acid Oleandrin may decrease the cardiotoxic activities of Nalidixic Acid. Approved, Investigational Namitecan Oleandrin may decrease the cardiotoxic activities of Namitecan. Investigational Navitoclax Oleandrin may decrease the cardiotoxic activities of Navitoclax. Investigational Neamine The serum concentration of Oleandrin can be decreased when it is combined with Neamine. Experimental Nebivolol Nebivolol may increase the bradycardic activities of Oleandrin. Approved, Investigational Nebularine Oleandrin may decrease the cardiotoxic activities of Nebularine. Experimental Necitumumab Oleandrin may decrease the cardiotoxic activities of Necitumumab. Approved, Investigational Nedaplatin Oleandrin may decrease the cardiotoxic activities of Nedaplatin. Approved, Investigational Nelarabine Oleandrin may decrease the cardiotoxic activities of Nelarabine. Approved, Investigational Neomycin The serum concentration of Oleandrin can be decreased when it is combined with Neomycin. Approved, Vet Approved Neosaxitoxin Neosaxitoxin may increase the arrhythmogenic activities of Oleandrin. Investigational Netilmicin The serum concentration of Oleandrin can be decreased when it is combined with Netilmicin. Approved, Investigational Niguldipine Oleandrin may decrease the cardiotoxic activities of Niguldipine. Experimental Nilotinib Oleandrin may decrease the cardiotoxic activities of Nilotinib. Approved, Investigational Nilutamide Oleandrin may decrease the cardiotoxic activities of Nilutamide. Approved, Investigational Nimustine Oleandrin may decrease the cardiotoxic activities of Nimustine. Investigational Nintedanib Oleandrin may decrease the cardiotoxic activities of Nintedanib. Approved Niraparib Oleandrin may decrease the cardiotoxic activities of Niraparib. Approved, Investigational Nivolumab Oleandrin may decrease the cardiotoxic activities of Nivolumab. Approved nocodazole Oleandrin may decrease the cardiotoxic activities of nocodazole. Experimental Nolatrexed Oleandrin may decrease the cardiotoxic activities of Nolatrexed. Investigational Norfloxacin Oleandrin may decrease the cardiotoxic activities of Norfloxacin. Approved Obinutuzumab Oleandrin may decrease the cardiotoxic activities of Obinutuzumab. Approved, Investigational Oblimersen Oleandrin may decrease the cardiotoxic activities of Oblimersen. Experimental, Investigational OBP-801 Oleandrin may decrease the cardiotoxic activities of OBP-801. Investigational Octreotide Oleandrin may decrease the cardiotoxic activities of Octreotide. Approved, Investigational Ofatumumab Oleandrin may decrease the cardiotoxic activities of Ofatumumab. Approved Ofloxacin Oleandrin may decrease the cardiotoxic activities of Ofloxacin. Approved Oglufanide Oleandrin may decrease the cardiotoxic activities of Oglufanide. Investigational Olaparib Oleandrin may decrease the cardiotoxic activities of Olaparib. Approved Olaratumab Oleandrin may decrease the cardiotoxic activities of Olaratumab. Approved, Investigational Oleandomycin The serum concentration of Oleandrin can be increased when it is combined with Oleandomycin. Vet Approved Olsalazine The serum concentration of Oleandrin can be decreased when it is combined with Olsalazine. Approved Oltipraz Oleandrin may decrease the cardiotoxic activities of Oltipraz. Investigational Omacetaxine mepesuccinate Oleandrin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate. Approved, Investigational Onapristone Oleandrin may decrease the cardiotoxic activities of Onapristone. Investigational Oprelvekin Oleandrin may decrease the cardiotoxic activities of Oprelvekin. Approved, Investigational Osimertinib Oleandrin may decrease the cardiotoxic activities of Osimertinib. Approved Oxaliplatin Oleandrin may decrease the cardiotoxic activities of Oxaliplatin. Approved, Investigational Oxolinic acid Oleandrin may decrease the cardiotoxic activities of Oxolinic acid. Experimental Oxprenolol Oxprenolol may increase the bradycardic activities of Oleandrin. Approved Paclitaxel Oleandrin may decrease the cardiotoxic activities of Paclitaxel. Approved, Vet Approved Paclitaxel poliglumex Oleandrin may decrease the cardiotoxic activities of Paclitaxel poliglumex. Experimental, Investigational Palbociclib Oleandrin may decrease the cardiotoxic activities of Palbociclib. Approved, Investigational Palifosfamide Oleandrin may decrease the cardiotoxic activities of Palifosfamide. Investigational Pamidronate Oleandrin may decrease the cardiotoxic activities of Pamidronate. Approved Pancuronium Pancuronium may increase the arrhythmogenic activities of Oleandrin. Approved Panitumumab Oleandrin may decrease the cardiotoxic activities of Panitumumab. Approved, Investigational Panobinostat Oleandrin may decrease the cardiotoxic activities of Panobinostat. Approved, Investigational Parathyroid hormone The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Oleandrin. Approved, Investigational Paricalcitol Paricalcitol may increase the arrhythmogenic activities of Oleandrin. Approved, Investigational Paromomycin The serum concentration of Oleandrin can be decreased when it is combined with Paromomycin. Approved, Investigational Patupilone Oleandrin may decrease the cardiotoxic activities of Patupilone. Experimental, Investigational Pazopanib Oleandrin may decrease the cardiotoxic activities of Pazopanib. Approved Pazufloxacin Oleandrin may decrease the cardiotoxic activities of Pazufloxacin. Investigational Pefloxacin Oleandrin may decrease the cardiotoxic activities of Pefloxacin. Approved Pegaspargase Oleandrin may decrease the cardiotoxic activities of Pegaspargase. Approved, Investigational Pembrolizumab Oleandrin may decrease the cardiotoxic activities of Pembrolizumab. Approved Pemetrexed Oleandrin may decrease the cardiotoxic activities of Pemetrexed. Approved, Investigational Penbutolol Penbutolol may increase the bradycardic activities of Oleandrin. Approved, Investigational Penclomedine Oleandrin may decrease the cardiotoxic activities of Penclomedine. Investigational Pentostatin Oleandrin may decrease the cardiotoxic activities of Pentostatin. Approved, Investigational Pertuzumab Oleandrin may decrease the cardiotoxic activities of Pertuzumab. Approved Phenethyl Isothiocyanate Oleandrin may decrease the cardiotoxic activities of Phenethyl Isothiocyanate. Investigational Phenylacetic acid Oleandrin may decrease the cardiotoxic activities of Phenylacetic acid. Approved Phenylbutyric acid Oleandrin may decrease the cardiotoxic activities of Phenylbutyric acid. Approved, Investigational Pindolol Pindolol may increase the bradycardic activities of Oleandrin. Approved, Investigational Pinometostat Oleandrin may decrease the cardiotoxic activities of Pinometostat. Investigational Pipecuronium Pipecuronium may increase the arrhythmogenic activities of Oleandrin. Approved Pipobroman Oleandrin may decrease the cardiotoxic activities of Pipobroman. Approved Pirarubicin Oleandrin may decrease the cardiotoxic activities of Pirarubicin. Investigational Piretanide The risk or severity of adverse effects can be increased when Piretanide is combined with Oleandrin. Approved Pirfenidone Oleandrin may decrease the cardiotoxic activities of Pirfenidone. Approved, Investigational Pirlindole Oleandrin may decrease the cardiotoxic activities of Pirlindole. Approved Pixantrone Oleandrin may decrease the cardiotoxic activities of Pixantrone. Approved, Investigational Platelet Activating Factor Platelet Activating Factor may increase the bradycardic activities of Oleandrin. Experimental Plazomicin The serum concentration of Oleandrin can be decreased when it is combined with Plazomicin. Approved, Investigational Plevitrexed Oleandrin may decrease the cardiotoxic activities of Plevitrexed. Investigational Plicamycin Oleandrin may decrease the cardiotoxic activities of Plicamycin. Approved, Investigational, Withdrawn Podofilox Oleandrin may decrease the cardiotoxic activities of Podofilox. Approved Podophyllin Oleandrin may decrease the cardiotoxic activities of Podophyllin. Approved Polythiazide The risk or severity of adverse effects can be increased when Polythiazide is combined with Oleandrin. Approved Pomalidomide Oleandrin may decrease the cardiotoxic activities of Pomalidomide. Approved Ponatinib Oleandrin may decrease the cardiotoxic activities of Ponatinib. Approved, Investigational Porfimer sodium Oleandrin may decrease the cardiotoxic activities of Porfimer sodium. Approved, Investigational Porfiromycin Oleandrin may decrease the cardiotoxic activities of Porfiromycin. Investigational Potassium Iodide The serum concentration of Oleandrin can be increased when it is combined with Potassium Iodide. Approved Practolol Practolol may increase the bradycardic activities of Oleandrin. Approved Pralatrexate Oleandrin may decrease the cardiotoxic activities of Pralatrexate. Approved, Investigational Prednimustine Oleandrin may decrease the cardiotoxic activities of Prednimustine. Investigational Prednisolone Oleandrin may decrease the cardiotoxic activities of Prednisolone. Approved, Vet Approved Prednisone Oleandrin may decrease the cardiotoxic activities of Prednisone. Approved, Vet Approved Primaquine The serum concentration of Oleandrin can be increased when it is combined with Primaquine. Approved Procarbazine Oleandrin may decrease the cardiotoxic activities of Procarbazine. Approved, Investigational Propafenone The serum concentration of Oleandrin can be increased when it is combined with Propafenone. Approved Propranolol Propranolol may increase the bradycardic activities of Oleandrin. Approved, Investigational Propylthiouracil The serum concentration of Oleandrin can be increased when it is combined with Propylthiouracil. Approved, Investigational Prulifloxacin Oleandrin may decrease the cardiotoxic activities of Prulifloxacin. Investigational Puromycin Oleandrin may decrease the cardiotoxic activities of Puromycin. Experimental Pyrantel Pyrantel may increase the arrhythmogenic activities of Oleandrin. Approved, Vet Approved Pyrazoloacridine Oleandrin may decrease the cardiotoxic activities of Pyrazoloacridine. Investigational Quinacrine Oleandrin may decrease the cardiotoxic activities of Quinacrine. Approved, Investigational Quinethazone The risk or severity of adverse effects can be increased when Quinethazone is combined with Oleandrin. Approved Quinidine The serum concentration of Oleandrin can be increased when it is combined with Quinidine. Approved, Investigational Rabusertib Oleandrin may decrease the cardiotoxic activities of Rabusertib. Investigational Radium Ra 223 Dichloride Oleandrin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride. Approved, Investigational Raltitrexed Oleandrin may decrease the cardiotoxic activities of Raltitrexed. Approved, Investigational Ramucirumab Oleandrin may decrease the cardiotoxic activities of Ramucirumab. Approved, Investigational Ranibizumab Oleandrin may decrease the cardiotoxic activities of Ranibizumab. Approved Ranimustine Oleandrin may decrease the cardiotoxic activities of Ranimustine. Experimental Ranpirnase Oleandrin may decrease the cardiotoxic activities of Ranpirnase. Investigational Rapacuronium Rapacuronium may increase the arrhythmogenic activities of Oleandrin. Withdrawn Regorafenib Oleandrin may decrease the cardiotoxic activities of Regorafenib. Approved Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Oleandrin. Approved, Investigational Resveratrol Oleandrin may decrease the cardiotoxic activities of Resveratrol. Approved, Experimental, Investigational Rhodamine 6G Oleandrin may decrease the cardiotoxic activities of Rhodamine 6G. Experimental Ribociclib Oleandrin may decrease the cardiotoxic activities of Ribociclib. Approved, Investigational Ribostamycin The serum concentration of Oleandrin can be decreased when it is combined with Ribostamycin. Approved, Investigational Ridaforolimus Oleandrin may decrease the cardiotoxic activities of Ridaforolimus. Investigational Rituximab Oleandrin may decrease the cardiotoxic activities of Rituximab. Approved Rocuronium Rocuronium may increase the arrhythmogenic activities of Oleandrin. Approved Romidepsin Oleandrin may decrease the cardiotoxic activities of Romidepsin. Approved, Investigational Roquinimex Oleandrin may decrease the cardiotoxic activities of Roquinimex. Investigational Rubitecan Oleandrin may decrease the cardiotoxic activities of Rubitecan. Investigational Rucaparib Oleandrin may decrease the cardiotoxic activities of Rucaparib. Approved, Investigational Rufloxacin Oleandrin may decrease the cardiotoxic activities of Rufloxacin. Experimental Ruxolitinib Oleandrin may decrease the cardiotoxic activities of Ruxolitinib. Approved Salirasib Oleandrin may decrease the cardiotoxic activities of Salirasib. Investigational Saracatinib Oleandrin may decrease the cardiotoxic activities of Saracatinib. Investigational Satraplatin Oleandrin may decrease the cardiotoxic activities of Satraplatin. Investigational Seliciclib Oleandrin may decrease the cardiotoxic activities of Seliciclib. Investigational Semaxanib Oleandrin may decrease the cardiotoxic activities of Semaxanib. Investigational Semustine Oleandrin may decrease the cardiotoxic activities of Semustine. Experimental, Investigational Seocalcitol Oleandrin may decrease the cardiotoxic activities of Seocalcitol. Experimental, Investigational Siltuximab Oleandrin may decrease the cardiotoxic activities of Siltuximab. Approved, Investigational Sirolimus Oleandrin may decrease the cardiotoxic activities of Sirolimus. Approved, Investigational Sisomicin The serum concentration of Oleandrin can be decreased when it is combined with Sisomicin. Investigational Sitafloxacin Oleandrin may decrease the cardiotoxic activities of Sitafloxacin. Experimental, Investigational Sizofiran Oleandrin may decrease the cardiotoxic activities of Sizofiran. Investigational Soblidotin Oleandrin may decrease the cardiotoxic activities of Soblidotin. Investigational Solithromycin The serum concentration of Oleandrin can be increased when it is combined with Solithromycin. Investigational Sonidegib Oleandrin may decrease the cardiotoxic activities of Sonidegib. Approved, Investigational Sorafenib Oleandrin may decrease the cardiotoxic activities of Sorafenib. Approved, Investigational Sotalol Sotalol may increase the bradycardic activities of Oleandrin. Approved Sparfloxacin Oleandrin may decrease the cardiotoxic activities of Sparfloxacin. Approved, Investigational Sparfosic acid Oleandrin may decrease the cardiotoxic activities of Sparfosic acid. Experimental Sparsomycin Oleandrin may decrease the cardiotoxic activities of Sparsomycin. Experimental Spiramycin The serum concentration of Oleandrin can be increased when it is combined with Spiramycin. Approved Spironolactone The therapeutic efficacy of Oleandrin can be decreased when used in combination with Spironolactone. Approved Squalamine Oleandrin may decrease the cardiotoxic activities of Squalamine. Investigational SRT501 Oleandrin may decrease the cardiotoxic activities of SRT501. Investigational Streptomycin The serum concentration of Oleandrin can be decreased when it is combined with Streptomycin. Approved, Vet Approved Streptozocin Oleandrin may decrease the cardiotoxic activities of Streptozocin. Approved, Investigational Succinylcholine Succinylcholine may increase the arrhythmogenic activities of Oleandrin. Approved Sulfasalazine The serum concentration of Oleandrin can be decreased when it is combined with Sulfasalazine. Approved Sulforaphane Oleandrin may decrease the cardiotoxic activities of Sulforaphane. Investigational Sulindac Oleandrin may decrease the cardiotoxic activities of Sulindac. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Oleandrin. Approved, Investigational Sunitinib Oleandrin may decrease the cardiotoxic activities of Sunitinib. Approved, Investigational Suramin Oleandrin may decrease the cardiotoxic activities of Suramin. Approved, Investigational Tafenoquine The serum concentration of Oleandrin can be increased when it is combined with Tafenoquine. Investigational Talaporfin Oleandrin may decrease the cardiotoxic activities of Talaporfin. Investigational Talazoparib Oleandrin may decrease the cardiotoxic activities of Talazoparib. Investigational Talinolol Talinolol may increase the bradycardic activities of Oleandrin. Investigational Tamoxifen Oleandrin may decrease the cardiotoxic activities of Tamoxifen. Approved Taselisib Oleandrin may decrease the cardiotoxic activities of Taselisib. Investigational Taurolidine Oleandrin may decrease the cardiotoxic activities of Taurolidine. Approved, Investigational Tegafur Oleandrin may decrease the cardiotoxic activities of Tegafur. Approved, Investigational Telithromycin The serum concentration of Oleandrin can be increased when it is combined with Telithromycin. Approved Telmisartan The serum concentration of Oleandrin can be increased when it is combined with Telmisartan. Approved, Investigational Temafloxacin Oleandrin may decrease the cardiotoxic activities of Temafloxacin. Withdrawn Temoporfin Oleandrin may decrease the cardiotoxic activities of Temoporfin. Approved, Investigational Temozolomide Oleandrin may decrease the cardiotoxic activities of Temozolomide. Approved, Investigational Temsirolimus Oleandrin may decrease the cardiotoxic activities of Temsirolimus. Approved Teniposide Oleandrin may decrease the cardiotoxic activities of Teniposide. Approved Terbutaline Terbutaline may increase the bradycardic activities of Oleandrin. Approved Tertatolol Tertatolol may increase the bradycardic activities of Oleandrin. Experimental Testolactone Oleandrin may decrease the cardiotoxic activities of Testolactone. Approved, Investigational Tezacitabine Oleandrin may decrease the cardiotoxic activities of Tezacitabine. Investigational Thalidomide Oleandrin may decrease the cardiotoxic activities of Thalidomide. Approved, Investigational, Withdrawn Thiotepa Oleandrin may decrease the cardiotoxic activities of Thiotepa. Approved, Investigational Thymalfasin Oleandrin may decrease the cardiotoxic activities of Thymalfasin. Approved, Investigational Tiazofurine Oleandrin may decrease the cardiotoxic activities of Tiazofurine. Experimental Tibolone Oleandrin may decrease the cardiotoxic activities of Tibolone. Approved, Investigational Timolol Timolol may increase the bradycardic activities of Oleandrin. Approved Tioguanine Oleandrin may decrease the cardiotoxic activities of Tioguanine. Approved Tiomolibdate ion Oleandrin may decrease the cardiotoxic activities of Tiomolibdate ion. Investigational Tipifarnib Oleandrin may decrease the cardiotoxic activities of Tipifarnib. Investigational Tirapazamine Oleandrin may decrease the cardiotoxic activities of Tirapazamine. Investigational Tivozanib Oleandrin may decrease the cardiotoxic activities of Tivozanib. Investigational Tobramycin The serum concentration of Oleandrin can be decreased when it is combined with Tobramycin. Approved, Investigational Tolevamer The risk or severity of adverse effects can be increased when Tolevamer is combined with Oleandrin. Approved, Investigational Topotecan Oleandrin may decrease the cardiotoxic activities of Topotecan. Approved, Investigational Torasemide The risk or severity of adverse effects can be increased when Torasemide is combined with Oleandrin. Approved Toremifene Oleandrin may decrease the cardiotoxic activities of Toremifene. Approved, Investigational Tositumomab Oleandrin may decrease the cardiotoxic activities of Tositumomab. Approved, Investigational Toyocamycin Oleandrin may decrease the cardiotoxic activities of Toyocamycin. Experimental Trabectedin Oleandrin may decrease the cardiotoxic activities of Trabectedin. Approved, Investigational Trametinib Oleandrin may decrease the cardiotoxic activities of Trametinib. Approved Transcrocetinate Oleandrin may decrease the cardiotoxic activities of Transcrocetinate. Investigational Trastuzumab Oleandrin may decrease the cardiotoxic activities of Trastuzumab. Approved, Investigational Trastuzumab emtansine Oleandrin may decrease the cardiotoxic activities of Trastuzumab emtansine. Approved, Investigational Trebananib Oleandrin may decrease the cardiotoxic activities of Trebananib. Investigational Tremelimumab Oleandrin may decrease the cardiotoxic activities of Tremelimumab. Investigational Treosulfan Oleandrin may decrease the cardiotoxic activities of Treosulfan. Investigational Tretamine Oleandrin may decrease the cardiotoxic activities of Tretamine. Experimental Tretazicar Oleandrin may decrease the cardiotoxic activities of Tretazicar. Investigational Tretinoin Oleandrin may decrease the cardiotoxic activities of Tretinoin. Approved, Investigational, Nutraceutical Triamterene The therapeutic efficacy of Oleandrin can be decreased when used in combination with Triamterene. Approved Triaziquone Oleandrin may decrease the cardiotoxic activities of Triaziquone. Experimental Trichlormethiazide The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Oleandrin. Approved, Vet Approved Trifluridine Oleandrin may decrease the cardiotoxic activities of Trifluridine. Approved, Investigational Trilostane Oleandrin may decrease the cardiotoxic activities of Trilostane. Approved, Investigational, Vet Approved, Withdrawn Trimetrexate Oleandrin may decrease the cardiotoxic activities of Trimetrexate. Approved, Investigational Triptolide Oleandrin may decrease the cardiotoxic activities of Triptolide. Investigational Triptorelin Oleandrin may decrease the cardiotoxic activities of Triptorelin. Approved, Vet Approved Trofosfamide Oleandrin may decrease the cardiotoxic activities of Trofosfamide. Investigational Trovafloxacin Oleandrin may decrease the cardiotoxic activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxacitabine Oleandrin may decrease the cardiotoxic activities of Troxacitabine. Investigational Tubercidin Oleandrin may decrease the cardiotoxic activities of Tubercidin. Experimental Tubocurarine Tubocurarine may increase the arrhythmogenic activities of Oleandrin. Approved Tylosin The serum concentration of Oleandrin can be increased when it is combined with Tylosin. Vet Approved Ubenimex Oleandrin may decrease the cardiotoxic activities of Ubenimex. Experimental, Investigational Uracil mustard Oleandrin may decrease the cardiotoxic activities of Uracil mustard. Approved Vadimezan Oleandrin may decrease the cardiotoxic activities of Vadimezan. Investigational Valrubicin Oleandrin may decrease the cardiotoxic activities of Valrubicin. Approved Vandetanib Oleandrin may decrease the cardiotoxic activities of Vandetanib. Approved Vapreotide Oleandrin may decrease the cardiotoxic activities of Vapreotide. Approved, Investigational Vecuronium Vecuronium may increase the arrhythmogenic activities of Oleandrin. Approved Veliparib Oleandrin may decrease the cardiotoxic activities of Veliparib. Investigational Vemurafenib Oleandrin may decrease the cardiotoxic activities of Vemurafenib. Approved Venetoclax Oleandrin may decrease the cardiotoxic activities of Venetoclax. Approved, Investigational Verapamil Verapamil may increase the atrioventricular blocking (AV block) activities of Oleandrin. Approved Verteporfin Oleandrin may decrease the cardiotoxic activities of Verteporfin. Approved, Investigational Vesnarinone Oleandrin may decrease the cardiotoxic activities of Vesnarinone. Investigational Vinblastine Oleandrin may decrease the cardiotoxic activities of Vinblastine. Approved Vincristine Oleandrin may decrease the cardiotoxic activities of Vincristine. Approved, Investigational Vindesine Oleandrin may decrease the cardiotoxic activities of Vindesine. Approved, Investigational Vinflunine Oleandrin may decrease the cardiotoxic activities of Vinflunine. Approved, Investigational Vinorelbine Oleandrin may decrease the cardiotoxic activities of Vinorelbine. Approved, Investigational Vintafolide Oleandrin may decrease the cardiotoxic activities of Vintafolide. Investigational Vismodegib Oleandrin may decrease the cardiotoxic activities of Vismodegib. Approved, Investigational Vitamin A Oleandrin may decrease the cardiotoxic activities of Vitamin A. Approved, Nutraceutical, Vet Approved Vorinostat Oleandrin may decrease the cardiotoxic activities of Vorinostat. Approved, Investigational Vorozole Oleandrin may decrease the cardiotoxic activities of Vorozole. Experimental Zorubicin Oleandrin may decrease the cardiotoxic activities of Zorubicin. Experimental Zuretinol acetate Oleandrin may decrease the cardiotoxic activities of Zuretinol acetate. Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Withdrawn Treatment Chemotherapeutic Agent Toxicity / Lung Cancers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00299 mg/mL ALOGPS logP 2.1 ALOGPS logP 2.95 ChemAxon logS -5.3 ALOGPS pKa (Strongest Acidic) 6.82 ChemAxon pKa (Strongest Basic) -3.2 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 7 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 120.75 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 148.45 m3·mol-1 ChemAxon Polarizability 63.2 Å3 ChemAxon Number of Rings 6 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Steroid lactones
- Direct Parent
- Cardenolide glycosides and derivatives
- Alternative Parents
- Steroidal glycosides / Steroid esters / 14-hydroxysteroids / Hexoses / O-glycosyl compounds / Oxanes / Butenolides / Dicarboxylic acids and derivatives / Tertiary alcohols / Enoate esters show 9 more
- Substituents
- Cardanolide-glycoside / Steroidal glycoside / Steroid ester / 14-hydroxysteroid / Hydroxysteroid / Hexose monosaccharide / Glycosyl compound / O-glycosyl compound / 2-furanone / Dicarboxylic acid or derivatives show 23 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- steroid ester, steroid saponin, 14beta-hydroxy steroid, cardenolide glycoside (CHEBI:59030)
Drug created on October 20, 2016 18:39 / Updated on July 02, 2018 19:42